Physician profile
Heidi Smith
NPI 1932748183
$1,893.03
in general payments reported to CMS, 2019-2025
21 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $756 · 2022: $619 · 2023: $375 · 2024: $15.43 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $518.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $510.01 | 2021-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $180.01 | 2021-2025 | Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $143.28 | 2021-2023 | |
| Esperion Therapeutics, INC. | $125.44 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $113.60 | 2021-2022 | |
| Exact Sciences Corporation | $110.53 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $107.13 | 2021-2022 | |
| Amarin Pharma, INC. | $81.60 | 2021 | |
| Janssen Pharmaceuticals, INC | $71.38 | 2021-2022 | |
| Abbvie INC. | $66.23 | 2025 | |
| Dexcom, INC. | $64.25 | 2021-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $52.98 | 2022-2023 | |
| Amgen INC. | $46.81 | 2021-2023 | Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $42.71 | 2023 | Keveyis, Gvoke Hypopen |
| Pfizer INC. | $34.15 | 2022-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.12 | 2022-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.98 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.01 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.70 | 2025 | Xifaxan |
| Horizon Therapeutics Plc | $18.77 | 2021 | |
| Amryt Pharma Holdings Ltd | $16.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.